Navigation Links
Benefit of PET and PET/CT in ovarian cancer is not proven
Date:8/8/2012

Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, in certain cases, recurrences can be detected earlier and more accurately with PET or PET/CT than with conventional imaging techniques. This is the conclusion of the final report by the German Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne that was published on 23 May 2012.

More reliable diagnosis is supposed to improve treatment

Ovarian cancer is the fifth most common malignant tumour in women. Every year 15.9 women in every 100,000 are diagnosed with the disease in Germany and it claims the lives of 8 in 100,000 women per year. Since the ovaries lie deep in the abdomen and an ovarian tumour normally causes no symptoms for a long time, it is often only discovered at a late stage.

Many experts hope that an investigation using PET or PET/CT alone or in combination with other methods would be better able to distinguish between benign and malignant tumours when ovarian cancer is suspected. It could also help classify cancerous tumours into the correct stage, make it easier to assess whether they respond to treatment and to show earlier and with greater certainty whether a recurrence or secondary tumour (metastasis) has occurred. This information should then enable patients to be given better treatment recommendations.

Benefit for patients is crucial

IQWiG therefore searched the international literature for studies investigating the effects of diagnosis using PET or PET/CT on health aspects of direct relevance to patients. For example, the results of this research - and an appropriately tailored treatment - could contribute to patients having better chances of survival, spare them unnecessary operations or other diagnostic procedures, or improve their quality of life. However, the search for such studies was unsuccessful, so the question as to the patient-relevant benefit of PET or PET/CT had to remain unanswered.

PET can better detect recurrences in certain cases

In addition, IQWiG searched for studies in which the diagnostic accuracy and prognostic power of PET or PET/CT were compared with other diagnostic methods. The basic question is how often a PET investigation gives a correct result. On the one hand, it should overlook true, cancerous tumours as rarely as possible, but on the other, it should not awake any false suspicions.

The results of a total of 40 individual studies on this topic were evaluated. However, these studies permit a robust conclusion only in respect of the detection (or exclusion) of a recurrence, where PET or PET/CT appears to be more reliable than other methods. Nevertheless, it remains unclear whether this only applies to patients in whom symptoms (e.g. pain) have already occurred, or also to those in whom routine screening has shown an abnormal blood test result. This is because only very few studies give precise details on this point.

Inform patients fully about benefits and harms

Since even the above patients have not been investigated to determine whether the higher test accuracy of PET or PET/CT has positive effects on mortality, the burden of disease or the quality of life, IQWiG assumes that a patient-relevant benefit of PET or PET/CT is not proven. For instance, it is particularly questionable whether a recurrence detected by PET or PET/CT can actually be better treated - and the patient thereby has a noticeable advantage.

It is therefore essential that doctors fully inform their patients not only of the possible benefits in the form of an earlier diagnosis, but also of the possible harms. The latter can arise from an earlier start to second-line treatment associated with considerable side effects, but not with a prolongation of survival. Hence studies are urgently needed to investigate the patient-relevant benefit of PET or PET/CT in the diagnosis of ovarian cancers in direct comparison with conventional diagnostic techniques.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Tafamidis: Approval denotes proven added benefit
2. Heart failure patients with diabetes may benefit from higher glucose levels
3. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
4. Avastin No Benefit to Older Lung Cancer Patients: Study
5. Talking to Yourself Could Have Mental Benefits
6. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
7. Research examines when benefits of screening mammography outweigh the harms for women in their 40s
8. Study finds that patient education videos viewed before an operation may benefit patients
9. Everyday fish oil capsule may provide kidney-related benefits
10. Erectile dysfunction drug may benefit cardiac function in young patients with heart defects
11. Study shows benefit of new maintenance therapy for multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale of ... revealing the skeletons in their closets. “They Sang At Her Funeral” is the creation ... young and married with five children and twelve grandchildren. Before becoming a writer, Annalise ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... McFarland has joined its executive team as the President of its HealthBI ... care management systems and contact centers. , “Scott is a utility player ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: